A Phase 2 interventional study of esketamine hydrochloride and propofol in Out-of-hospital Cardiac Arrest (OHCA), sponsored by Christian Hassager. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.
Sponsored by Christian Hassager · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark — 7 open to participants now, 8 under way, 2 of them phase 3. Out-of-Hospital Cardiac Arrest · Denmark.
Among the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2024, is one of 4 in phase 2, and was the 36th registered.
314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.
Browse Out-of-Hospital Cardiac Arrest studies →7 of the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark are open now. Recruiting first, the newest first:
Lars Wiuff Andersen · Sites in Denmark
Ages 18+
Emergency Medical Services, Capital Region, Denmark · Sites in Denmark
Ages 8+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Bo Gregers Winkel · Sites in Denmark
Ages 18+
Invero Pharma, Inc. · Sites in Denmark, United States
Ages 18–80
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 282 is above the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.
Median enrollment 376 across the 26 interventional studies, 900 across the 12 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 38 have an industry lead sponsor. The 10 most frequent:
Christian Hassager is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Christian Hassager has 4 studies filed under Out-of-Hospital Cardiac Arrest — fewer than ten, so there is no comparison to draw.
3 of the studies in Out-of-Hospital Cardiac Arrest with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05895838Phase 3Christian HassagerThe Danish Out-of-Hospital Cardiac Arrest Study | 2027-09 |
| NCT04446585Emergency Medical Services, Capital Region, DenmarkCardiac Arrest in Residential Areas With Mobile First-responder Activation | 2027-01 |
| NCT06744361Christian HassagerKetamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
OHCA is a critical medical emergency with significant mortality and morbidity primarily due to hypoxic-ischemic brain injury (HIBI). Despite advances in resuscitation techniques, the neurological outcomes for survivors remain poor. Current post-resuscitation practices lack specific neuroprotective strategies. Ketamine, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, has shown potential neuroprotective properties in preclinical and clinical studies due to its ability to inhibit excitotoxicity and reduce neuronal apoptosis. This trial hypothesizes that ketamine, when used for sedation in OHCA patients, may offer superior neuroprotective benefits compared to the commonly used sedative propofol. By comparing the effects of ketamine and propofol on neuronal damage markers and long-term neurological outcomes, this study aims to identify a potentially effective intervention to improve the prognosis of OHCA patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intravenous or intraosseous bolus administration at a minimum of 0.5 mg/kg of esketamine
Drug: esketamine hydrochloride
Prehospital intravenous or intraosseous bolus administration of a minimum dose of 0.25 mg/kg propofol
Drug: propofol
Prehospital intravenous or intraosseous bolus administration at a minimum of 0.5 mg/kg of esketamine
Prehospital intravenous or intraosseous bolus administration at a minimum dose of 0.25 mg/kg propofol
Neuron-specific enolase (NSE) measured 48 hours after OHCA
To determine the neuroprotective efficacy of ketamine compared with propofol administered as part of sedation for intubation after initial resuscitation from OHCA
Time frame: 48 hours after OHCA
Death from any cause
Death from any cause 180 days after cardiac arrest
Time frame: 180 days after cardiac arrest
Neurological outcome: modified Rankin Score (mRS)
Neurological outcome by and modified Rankin Score (mRS). Meassured from 0 to 6, where 0 is no symptoms.
Time frame: At 2 weeks (at discharge)
Neurological outcome: Cerebral Performance Categories (CPC)
Neurological outcome by Cerebral Performance Categories (CPC) meassured fra 1-5 (a score of 1 is normal/good cerebral function).
Time frame: At 2 weeks (at discharge)
Neurological outcome: modified Rankin Score (mRS)
Neurological outcome by and modified Rankin Score (mRS). Meassured from 0 to 6, where 0 is no symptoms.
Time frame: At 180 days after OHCA.
Neurological outcome: modified Rankin Score (mRS)
Neurological outcome by and modified Rankin Score (mRS). Meassured from 0 to 6, where 0 is no symptoms.
Time frame: At 240 days after OHCA.
Neurological outcome: Cerebral Performance Categories (CPC)
Neurological outcome by Cerebral Performance Categories (CPC) meassured fra 1-5 (a score of 1 is normal/good cerebral function).
Time frame: At 180 days after OHCA.
Neurological outcome: Cerebral Performance Categories (CPC)
Neurological outcome by Cerebral Performance Categories (CPC) meassured fra 1-5 (a score of 1 is normal/good cerebral function).
Time frame: At 240 days after OHCA.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Sep 2027, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine
Out-of-Hospital Cardiac Arrest →
Christian Hassager